BR9812687A - Formulação de comprimido para liberação contìnua para tratar doença de parkinson - Google Patents

Formulação de comprimido para liberação contìnua para tratar doença de parkinson

Info

Publication number
BR9812687A
BR9812687A BR9812687-3A BR9812687A BR9812687A BR 9812687 A BR9812687 A BR 9812687A BR 9812687 A BR9812687 A BR 9812687A BR 9812687 A BR9812687 A BR 9812687A
Authority
BR
Brazil
Prior art keywords
disease
continuous
tablet formulation
release tablet
treat parkinson
Prior art date
Application number
BR9812687-3A
Other languages
English (en)
Inventor
Tzu-Chi Robert Ju
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR9812687A publication Critical patent/BR9812687A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<B>FORMULAçãO DE COMPRIMIDO PARA LIBERAçãO CONTìNUA PARA TRATAR DOENçA DE PARKINSON<D> O comprimido de liberação contínua de (R) -5,6-diidro-5- (metilamino) -4H-imidazo [4,5-ij] -quinolina-2 (1H) -ona (Z) -2-butenodioato (1:1), que é revelado, permite a administração duas vezes por dia de (R) -5,6-diidro-5- (metilamino) -4H-imidazo [4,5-ij] -quinolina-2 (1H) -ona (Z) -2-butenodioato (1:1) para tratar seres humanos com doenças de Parkinson.
BR9812687-3A 1997-09-30 1998-09-03 Formulação de comprimido para liberação contìnua para tratar doença de parkinson BR9812687A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6082797P 1997-09-30 1997-09-30
PCT/US1998/017992 WO1999016442A2 (en) 1997-09-30 1998-09-03 Sustained release tablet formulation to treat parkinson disease

Publications (1)

Publication Number Publication Date
BR9812687A true BR9812687A (pt) 2000-08-22

Family

ID=22031996

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812687-3A BR9812687A (pt) 1997-09-30 1998-09-03 Formulação de comprimido para liberação contìnua para tratar doença de parkinson

Country Status (23)

Country Link
US (2) US6197339B1 (pt)
EP (1) EP1017391B1 (pt)
JP (1) JP2001517701A (pt)
KR (1) KR100516095B1 (pt)
CN (1) CN1195518C (pt)
AT (1) ATE297208T1 (pt)
AU (1) AU742941B2 (pt)
BR (1) BR9812687A (pt)
CA (1) CA2301869A1 (pt)
DE (1) DE69830503T2 (pt)
DK (1) DK1017391T3 (pt)
ES (1) ES2242296T3 (pt)
FI (1) FI20000720A (pt)
HK (1) HK1030163A1 (pt)
HU (1) HUP0004586A2 (pt)
NO (1) NO320303B1 (pt)
NZ (1) NZ504221A (pt)
PL (1) PL191125B1 (pt)
PT (1) PT1017391E (pt)
RU (1) RU2205007C2 (pt)
SI (1) SI1017391T1 (pt)
SK (1) SK3612000A3 (pt)
WO (1) WO1999016442A2 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767089B2 (en) 1999-02-05 2003-10-30 Pharmacia & Upjohn Company Process to prepare (5R)-(methylamino)-5,6-dihydro-4H- imidazo(4,5,1-ij)-quinolin-2(1H)-one
KR100660594B1 (ko) 1999-03-31 2006-12-22 얀센 파마슈티카 엔.브이. 방출 조절형 제제중의 프리젤라틴화 전분
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
PT1453505E (pt) * 2001-12-11 2010-12-16 Univ Virginia Utilização de pramipexol para tratamento da esclerose lateral amiotrófica
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
CA2479350A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
US20050079217A1 (en) * 2002-07-25 2005-04-14 Ganorkar Loksidh D. Sustained-release tablet composition comprising a dopamine receptor agonist
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
AR040682A1 (es) 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
US20040138200A1 (en) * 2002-10-04 2004-07-15 Michael Hawley Pharmaceutical compositions for treatment of Parkinson's disease
BR0314525A (pt) * 2002-10-04 2005-07-26 Pharmacia Corp Composições e métodos para tratamento de disfunção sexual
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
AU2003267769A1 (en) * 2002-10-25 2004-05-13 Pharmacia & Upjohn Company Llc Use of heterocyclic amine-type compounds as neuroprotective agents
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20040228830A1 (en) * 2003-01-28 2004-11-18 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
US20050020589A1 (en) * 2003-06-18 2005-01-27 Pfizer Inc. Sustained-release tablet composition comprising a dopamine receptor agonist
EP2431027A1 (en) * 2004-08-13 2012-03-21 Boehringer Ingelheim International GmbH Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
BRPI0513847A (pt) * 2004-08-13 2008-05-20 Boehringer Ingelheim Int formulação de comprimido de liberação extendida contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e uso do mesmo
EP1917014B1 (en) * 2005-08-15 2009-10-07 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
WO2007137071A2 (en) 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of r(+) and s(-) pramipexole and methods of using the same
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CN101715443A (zh) 2007-03-14 2010-05-26 诺普神经科学股份有限公司 手性纯化的取代的苯并噻唑二胺的合成
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
KR101684750B1 (ko) 2011-09-23 2016-12-08 로슈 글리카트 아게 이중특이적 항-egfr/항-igf-1r 항체
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9463186B2 (en) 2013-04-15 2016-10-11 Northwestern University Treatment for dopaminergic disorders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US10828284B2 (en) 2013-07-12 2020-11-10 Knopp Biosciences Llc Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
AU2014306597B2 (en) 2013-08-13 2018-05-17 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
CA2921378A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
KR0167346B1 (ko) * 1989-06-09 1999-01-15 로버트 에이. 아미테이지 중추신경계 활성을 갖는 헤테로사이클릭 아민
US5273975A (en) 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
US5000962A (en) 1989-08-25 1991-03-19 Schering Corporation Long acting diltiazem formulation
GB9605857D0 (en) 1996-03-20 1996-05-22 Tester Richard F Polysaccharides as chemical release systems
CA2173818A1 (fr) 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
PL191125B1 (pl) 2006-03-31
DE69830503T2 (de) 2006-03-16
FI20000720A (fi) 2000-03-29
NZ504221A (en) 2004-11-26
NO20001624D0 (no) 2000-03-29
PT1017391E (pt) 2005-09-30
KR20010030776A (ko) 2001-04-16
US6197339B1 (en) 2001-03-06
WO1999016442A3 (en) 1999-06-17
WO1999016442A2 (en) 1999-04-08
SI1017391T1 (sl) 2005-12-31
DK1017391T3 (da) 2005-08-22
CN1268890A (zh) 2000-10-04
ATE297208T1 (de) 2005-06-15
EP1017391A2 (en) 2000-07-12
EP1017391B1 (en) 2005-06-08
KR100516095B1 (ko) 2005-09-23
CA2301869A1 (en) 1999-04-08
NO320303B1 (no) 2005-11-21
SK3612000A3 (en) 2000-09-12
JP2001517701A (ja) 2001-10-09
AU9296498A (en) 1999-04-23
AU742941B2 (en) 2002-01-17
PL339946A1 (en) 2001-01-15
CN1195518C (zh) 2005-04-06
HUP0004586A2 (hu) 2001-06-28
DE69830503D1 (de) 2005-07-14
US20010053386A1 (en) 2001-12-20
RU2205007C2 (ru) 2003-05-27
HK1030163A1 (en) 2001-04-27
NO20001624L (no) 2000-03-29
ES2242296T3 (es) 2005-11-01

Similar Documents

Publication Publication Date Title
BR9812687A (pt) Formulação de comprimido para liberação contìnua para tratar doença de parkinson
EE9900465A (et) Uued ühendid
AR022665A1 (es) Compuestos farmaceuticamente activos
ES2091689T3 (es) Aplicacion de la carbamazepina y de la oxcarbazepina en el tratamiento de la enfermedad de parkinson y de los sindromes parkinsonianos.
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
PT991653E (pt) Novos compostos
AR009937A1 (es) Pirimido [5,4-d] pirimidinas, medicamentos que contienen estos compuestos, su empleo y procedimiento para su preparacion
EE9900315A (et) Pürrolo[3,4-d]pürimidinooni derivaadid ja nende kasutamine ravimitena
UY26370A1 (es) &#34;imidazo-5-il-aminas bicíclicas, medicamentos que las contienen, su uso para la preparación de medicamentos y procedimiento para su preparación&#34;.
NO20013645L (no) Anvendelse av pyridazino[4,5-b]indol-1-acetamid-derivater for fremstilling av medisiner for behandling av sykdommer relatert tildysfunksjon av de perifere benzodiazepinreseptorer
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
ES2043665T3 (es) 6,11-dihidro-11-(4-piperidiliden)-5h-benzo-(5,6)-ciclohepta-(1,2-b)-piridinas y composiciones y metodos de uso.
RS49746B (sr) Supstituisani derivat triazolo- piradizina, farmaceutske smeše koje se sa njim proizvode
HUP0101803A2 (hu) Cabergolin és pramipexol új alkalmazása gyógyszerkészítmények előállítására
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
BR0015938A (pt) Uso de antagonistas beta-adrenoceptores para a fabricação de um medicamento para o tratamento de desordens da retina externa
UY26224A1 (es) Complejo farmaceutico ley 17164 art. 127
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
AR005958A1 (es) Acidos 8-cian-1-ciclopropil-7-(2,8-diazabiciclo[4.3.0]-nonan-8-il)-6-fluor-1,4-dihidro-4-oxo-3-quinolincarboxilicos, opcionalmente substituidos, y sus derivados, procedimiento para su obtencion, medicamentos que los contienen y su empleo para la fabricacion de medicamentos y como agentes antibacterianos
AR026756A1 (es) Nuevas combinaciones terapeuticas (s)-2-bencilamino-metil)-2,3,8,9-tetrahidro-7h-1,4-dioxino[2,3-e]indol-8-ona y neuroleticos para el tratamiento oprevencion de desordenes psicoticos
AR018171A1 (es) Compuestos de 2-metil-4-(4-metil-1-piperazinil)10 h-tieno [2,3-b] [1.5] benzodiazepina-olanzapina- como sal pamoato de la misma, solvatos de dicha sal y uso de los mismos para preparar composiciones para el tratamiento de animales, inclusive al hombre que padece psicosis, manias agudas o estados lev
ECSP993045A (es) Derivados de acridina, procedimiento para su preparacion y su utilizacion como analgesico
PE20010752A1 (es) Uso de desloratadina para el tratamiento de estados alergicos e inflamatorios
BR0113517A (pt) 2,5-dihidro-pirazolo[3,4-d] pirimidin-4-onas de efeito anticonvulsivo e processos para preparação dos mesmos
AU4123297A (en) Alkaloid glycoside for use as a medicament

Legal Events

Date Code Title Description
B09B Patent application refused [chapter 9.2 patent gazette]